Found: 45
Select item for more details and to access through your institution.
Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial.
- Published in:
- 2014
- By:
- Publication type:
- journal article
The effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) diary: pooled analysis of two 6-month Phase III studies.
- Published in:
- 2016
- By:
- Publication type:
- journal article
GOLD assessment of COPD severity in the Clinical Practice Research Datalink (CPRD).
- Published in:
- Pharmacoepidemiology & Drug Safety, 2019, v. 28, n. 2, p. 126, doi. 10.1002/pds.4448
- By:
- Publication type:
- Article
ACCORD COPD II: A Randomized Clinical Trial to Evaluate the 12-Week Efficacy and Safety of Twice-Daily Aclidinium Bromide in Chronic Obstructive Pulmonary Disease Patients.
- Published in:
- Clinical Drug Investigation, 2013, v. 33, n. 12, p. 893, doi. 10.1007/s40261-013-0138-1
- By:
- Publication type:
- Article
Baseline type 2 biomarker levels and response to tezepelumab in severe asthma.
- Published in:
- Allergy, 2022, v. 77, n. 6, p. 1786, doi. 10.1111/all.15197
- By:
- Publication type:
- Article
Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis.
- Published in:
- Allergy, 2022, v. 77, n. 1, p. 150, doi. 10.1111/all.14902
- By:
- Publication type:
- Article
Pharmacokinetics and safety of aclidinium bromide in younger and elderly patients with chronic obstructive pulmonary disease.
- Published in:
- International Journal of Clinical Pharmacology & Therapeutics, 2012, v. 50, n. 6, p. 403, doi. 10.5414/CP201628
- By:
- Publication type:
- Article
Use of concomitant inhaled corticosteroids: pooled data from two phase III studies of aclidinium plus formoterol in COPD.
- Published in:
- NPJ Primary Care Respiratory Medicine, 2017, p. 1, doi. 10.1038/s41533-016-0009-3
- By:
- Publication type:
- Article
The Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide 400 μg Administered by Inhalation as Single and Multiple (Twice Daily) Doses in Healthy Chinese Participants.
- Published in:
- International Journal of COPD, 2023, v. 18, p. 2725, doi. 10.2147/COPD.S434588
- By:
- Publication type:
- Article
Differential Outcomes Following 4 Weeks of Aclidinium/Formoterol in Patients with COPD: A Reanalysis of the ACTIVATE Study.
- Published in:
- International Journal of COPD, 2022, v. 17, p. 517, doi. 10.2147/COPD.S308600
- By:
- Publication type:
- Article
The Impact of Exacerbation History on the Safety and Efficacy of Aclidinium in Patients with Chronic Obstructive Pulmonary Disease and Increased Cardiovascular Risk: ASCENT-COPD Trial.
- Published in:
- International Journal of COPD, 2021, v. 16, p. 689, doi. 10.2147/COPD.S285068
- By:
- Publication type:
- Article
AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD.
- Published in:
- International Journal of COPD, 2019, v. 14, p. 667, doi. 10.2147/COPD.S189138
- By:
- Publication type:
- Article
The Impact of Lebrikizumab on Vaccine-Induced Immune Responses: Results from a Phase 3 Study in Adult Patients with Moderate-to-Severe Atopic Dermatitis.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 8, p. 2181, doi. 10.1007/s13555-024-01217-w
- By:
- Publication type:
- Article
Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic Dermatitis.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 7, p. 1929, doi. 10.1007/s13555-024-01199-9
- By:
- Publication type:
- Article
Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease: The ASCENT-COPD Randomized Clinical Trial.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Efficacy of Aclidinium Bromide According to Baseline Therapy: Post-Hoc Analysis of ASCENT-COPD Randomized Trial.
- Published in:
- Advances in Therapy, 2021, v. 38, n. 10, p. 5381, doi. 10.1007/s12325-021-01878-5
- By:
- Publication type:
- Article
Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT.
- Published in:
- International Journal of COPD, 2019, v. 14, p. 479, doi. 10.2147/COPD.S185502
- By:
- Publication type:
- Article
Evaluation of the psychometric properties of the Early Morning Symptoms of COPD Instrument (EMSCI).
- Published in:
- International Journal of COPD, 2018, v. 13, p. 1633, doi. 10.2147/COPD.S152087
- By:
- Publication type:
- Article
ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD.
- Published in:
- International Journal of COPD, 2017, v. 12, p. 2545, doi. 10.2147/COPD.S143488
- By:
- Publication type:
- Article
Improvement in 24-hour bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study.
- Published in:
- International Journal of COPD, 2017, v. 12, p. 1731, doi. 10.2147/COPD.S121723
- By:
- Publication type:
- Article
Impact of night-time symptoms in COPD: a real-world study in five European countries.
- Published in:
- International Journal of COPD, 2013, v. 8, p. 595, doi. 10.2147/COPD.S48570
- By:
- Publication type:
- Article
Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT).
- Published in:
- Respiratory Research, 2015, v. 16, n. 1, p. 1, doi. 10.1186/s12931-015-0250-2
- By:
- Publication type:
- Article
Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT)
- Published in:
- Respiratory Research, 2015, v. 16, n. 1, p. 92, doi. 10.1186/s12931-015-0250-2
- By:
- Publication type:
- Article
Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT).
- Published in:
- 2015
- By:
- Publication type:
- journal article
Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Mass balance and metabolism of aclidinium bromide following intravenous administration of [<sup>14</sup>C]-aclidinium bromide in healthy subjects.
- Published in:
- Biopharmaceutics & Drug Disposition, 2012, v. 33, n. 1, p. 39, doi. 10.1002/bdd.1773
- By:
- Publication type:
- Article
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.
- Published in:
- British Journal of Dermatology, 2023, v. 188, n. 6, p. 740, doi. 10.1093/bjd/ljad022
- By:
- Publication type:
- Article
314 Injection site reactions from an integrated analysis of phase 2 and phase 3 clinical trials of lebrikizumab treatment in moderate-to-severe atopic dermatitis.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. ii8, doi. 10.1093/bjd/ljac140.011
- By:
- Publication type:
- Article
Long-acting antimuscarinic therapy in patients with chronic obstructive pulmonary disease receiving beta-blockers.
- Published in:
- 2021
- By:
- Publication type:
- journal article
NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma.
- Published in:
- 2020
- By:
- Publication type:
- journal article
SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial.
- Published in:
- BMC Pulmonary Medicine, 2014, v. 14, n. 1, p. 301, doi. 10.1186/1471-2466-14-209
- By:
- Publication type:
- Article
Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORMCOPD): a multicentre, randomised study.
- Published in:
- BMC Pulmonary Medicine, 2014, v. 14, n. 1, p. 1, doi. 10.1186/1471-2466-14-178
- By:
- Publication type:
- Article
Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Activity of aclidinium bromide, a new long-acting muscarinic antagonist: a phase I study.
- Published in:
- British Journal of Clinical Pharmacology, 2010, v. 69, n. 5, p. 458, doi. 10.1111/j.1365-2125.2010.03622.x
- By:
- Publication type:
- Article
An Evaluation of the Pharmacokinetics, Safety, and Tolerability of Aclidinium/Formoterol Fixed-Dose Combination Administered in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease.
- Published in:
- Drugs in R&D, 2022, v. 22, n. 1, p. 35, doi. 10.1007/s40268-021-00374-z
- By:
- Publication type:
- Article
Characterization of Patients in the International Severe Asthma Registry with High Steroid Exposure Who Did or Did Not Initiate Biologic Therapy.
- Published in:
- Journal of Asthma & Allergy, 2022, v. 15, p. 1491, doi. 10.2147/JAA.S377174
- By:
- Publication type:
- Article
Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study.
- Published in:
- Journal of Asthma & Allergy, 2022, v. 15, p. 63, doi. 10.2147/JAA.S328653
- By:
- Publication type:
- Article
Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.
- Published in:
- 2017
- By:
- Publication type:
- journal article
619 - Lebrikizumab improves signs and symptoms of moderate-to-severe atopic dermatitis in patients not adequately controlled or non-eligible for cyclosporine: a placebo-controlled, randomized phase 3 clinical study (ADvantage).
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.005
- By:
- Publication type:
- Article
Lebrikizumab does not impact vaccine-induced immune responses: results from a phase 3 study in adult patients with moderate-to-severe atopic dermatitis.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii3, doi. 10.1093/bjd/ljad498.004
- By:
- Publication type:
- Article
Safety and Tolerability of Aclidinium Administered Intravenously and Absolute Bioavailability of Inhaled Aclidinium in Healthy Male Participants.
- Published in:
- Journal of Clinical Pharmacology, 2012, v. 52, n. 6, p. 819, doi. 10.1177/0091270011406281
- By:
- Publication type:
- Article
Aclidinium Bromide, a Long-Acting Antimuscarinic, Does Not Affect QT Interval in Healthy Subjects.
- Published in:
- Journal of Clinical Pharmacology, 2011, v. 51, n. 6, p. 923, doi. 10.1177/0091270010374471
- By:
- Publication type:
- Article
Use of CompEx in eosinophilic patients with severe, uncontrolled asthma on benralizumab.
- Published in:
- ERJ Open Research, 2024, v. 10, n. 2, p. 1, doi. 10.1183/23120541.01025-2023
- By:
- Publication type:
- Article